
Center for Medical Ethics and Health Policy Staff Publications
Publication Date
6-13-2025
Journal
Neoplasia
DOI
10.1016/j.neo.2025.101185
PMID
40516145
PMCID
PMC12205659
PubMedCentral® Posted Date
6-13-2025
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Lung cancer, Cigarette smoke, Electronic cigarette, Kras, Microbiome
Abstract
Despite the emerging public health concern related to the use of electronic cigarette vapors (ECV), its impact on lung cancer is poorly understood. We assessed the effect of ECV on lung tumorigenesis in a mouse model of lung adenocarcinoma. Mice were exposed to either room air, combustible cigarette smoke (CCS), or ECV 2 hours daily for 8 weeks at which lung samples were harvested and studied for different outcomes. We found that CCS, but not ECV, led to a significant increase in tumor burden. Immunophenotyping of both CCS- and ECV-exposed lungs displayed pronounced pro-tumor immunosuppressive phenotypes, characterized by significantly decreased CD4+ IFNγ+ and CD8+ GZMB+ T cells along with an elevated CD4+ FOXP3+ regulatory T cells. However, differential changes in myeloid cells were observed between CCS and ECV-exposed lungs. A microbiome profiling of matched stool and lung samples showed differences in the relative abundance of lung Pseudomonadotas, while gut Bacillota, particularly Turicibacter, and Ileibacterium were increased by CCS and ECV. We conclude that both CCS and ECV exposure under the applied regimen lead to a protumor immune suppressive lung microenvironment although with different magnitudes and slightly different phenotypes that might explain their differential effects on tumor burden warranting further studies.
Included in
Bioethics and Medical Ethics Commons, Health Policy Commons, Medical Sciences Commons, Oncology Commons, Pulmonology Commons